Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2785917 | 0.79 | DGAT1 (0.31) | — | |
| SCHEMBL569888 | 0.79 | DGAT1 (0.31) | — | |
| SCHEMBL136090 | 0.77 | HPGD (0.31) | — | |
| SCHEMBL5421441 | 0.77 | HPGD (0.31) | — | |
| SCHEMBL27507934 | 0.75 | SMYD3 (0.38) | — | |
| SCHEMBL25473022 | 0.74 | ALDH1A1 (0.31) | CHRM2CHRM1CHRM3 | |
| SCHEMBL27273077 | 0.74 | ALDH1A1 (0.31) | CHRM2CHRM1CHRM3 | |
| SCHEMBL7575563 | 0.71 | — | — | |
| SCHEMBL28025816 | 0.70 | GAA (0.38) | CHRM2CHRM1CHRM3 | |
| SCHEMBL25962672 | 0.68 | NFKB1 (0.31) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| CN-1138546-C | Certain 1, 4, 5 -tri- substituted imidazole compounds useful as cytokine | ʷ��˿�������ȳ�ķ����˾ | 2004-02-18 | — | — | CN | disclosed |
| CN-1130358-C | Imidazole compound and preparation method and application thereof | SMITHKLINE BEECHAM CORP (US) | 2003-12-10 | — | — | CN | disclosed |
| WO-2003037271-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS,INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| CN-1213306-A | Novel substituted imidazolium compounds | SMITHKLINE BEECHAM CORP (US) | 1999-04-07 | — | — | CN | disclosed |
| CN-1213307-A | Novel substituted imidazolium compounds | SMITHKLINE BEECHAM CORP (US) | 1999-04-07 | — | — | CN | disclosed |
| CN-1192147-A | Imidazole compounds | SMITHKLINE BEECHAM CORP (US) | 1998-09-02 | — | — | CN | disclosed |
| CN-1177299-A | Certain 1, 4, 5 -tri- substituted imidazole compounds useful as cytokine | SMITHKLINE BEECHAM CORP (US) | 1998-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | CHRM2 1996/4885CHRM1 2534/4885CHRM3 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.